Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies

American Heart Journal

Volumn 138, Issue 3 I, 1999, Pages 577-585

  Nakamura, Y ^a   Moss, A J ^a   Brown, M W ^a   Kinoshita, M ^a   Kawai, C ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRATE;

ADULT; ARTICLE; DATA BASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 0032861874     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70163-8     Document Type: Article

References (44)

1. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981;246:2073-4.
2. Pedersen TR. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985; 313:1055-8.
3. The Israeli SPRINT Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.
4. The Multicenter Diltiazem Post-infarction Trial Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
5. Stein B, Fuster V. Role of platelet inhibitor therapy in myocardial infarction. Cardiovasc Drugs Ther 1989;3:797-813.
6. Moss AJ, Goldstein RE, Hall WJ, et al. Detection and significance of myocardial ischemia in stable patients after recovery from an acute coronary event. JAMA 1993;269:2379-85.
7. Nakamura Y, Kawai C, Moss AJ, et al. Comparison between Japan and North America in the posthospital course after recovery from an acute coronary event. Int J Cardiol 1996;55:245-54.
8. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
9. Rubin DB. Estimating causal effects from large data set using propensity score. Ann Intern Med 1997;127:757-63.
10. Cox DR. Regression models and life-tables. J R Stat Soc Bull 1972; 34:187-220.
11. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stats Med 1996;15:361-87.
12. Rosenbaum PR, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. J R Statist Soc Bull 1983;45:212-8.
13. Bussmann WD, Passek D, Seidel W, Kaltenbach M. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 1981;63:615-22.
14. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988;78:906-19.
15. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function alter acute myocardial infarction. Lancet 1994;343:1115-22.
16. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trail assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
17. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increased cardiac events in patients with healed myocardial infarction. Jpn Circ J 1996;60:779-88.
18. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313.
19. Jugdutt BI, Warnica JW. Tolerance to low dose intravenous nitroglycerin in acute myocardial infarction. Am J Cardiol 1989;64:581-7.
20. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
21. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994;128:137-46.
22. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:789-93.
23. Amsterdam EA. Rationale for intermittent nitrate therapy. Am J Cardiol 1992;70:55G-60G.
24. Frishman WH. Tolerance, rebound, and time-zero effect of nitrate therapy. Am J Cardiol 1992;70:43G-48G.
25. Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ 1988;297:1227-30.
26. Keller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73:114-23.
27. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-31.
28. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995;76:24C-33C.
29. Feelisch M. Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J 1993;14(Suppl I):123-32.
30. Moore KP, Usmar VD, Morrow J, Roberts LJ II. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res 1995;77:335-41.
31. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30 days mortality in the era of reperfusion for acute myocardial infarction. Results from an International Trial of 41,021 patients. Circulation 1995; 91:1659-68.
32. Volpi A, De Vita A, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI2 data base. Circulation 199388:416-29.
33. Komowski R, Goldbourt U, Zion M, et al. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardiol 1993;72:883-8.
34. Kannel WB, Softie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham Study. Am J Cardiol 1979;44:53.
35. Greenland P, Reicher-Reiss H, Goldbourt U, et al. Inhospital and 1-year mortality in 1524 women after myocardial infarction. Comparison with 4315 men. Circulation 1993;83:484-91.
36. Puletti M, Sunseri L, Curione M, et al. Acute myocardial infarction: sex-related difference in prognosis. Am Heart J 1984;108:63-6.
37. Steingart RM, Packer M, Hamm P, et al. Sex difference in the management of coronary artery disease. N Engl J Med 1991325:226-30.
38. Maynard C, Althouse R, Cerqueira M, et al. Underutilization of thrombolytic therapy in eligible women with acute myocardial infarction. Am J Cardiol 1991;68:529-30.
39. Krumholz HM, Douglas PS, Lauer MS, et al. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for gender bias? Ann Intern Med 1992;116:785-90.
40. Ayanian JZ, Epstein AM. Difference in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991;325:221-5.
41. White HD, Barbash Gl, Modan M, et al. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation 1993;88:2097-103.
42. Lincoff AM, Califf RM, Ellis SG, et al. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? J Am Coll Cardiol 1993;22:1780-7.
43. Stein B, Fuster V. Role of platelet inhibitor therapy in myocardial infarction. Cardiovasc Drugs Ther 1989;3:797-813.
44. Elwood PC. Aspirin in the prevention of myocardial infarction. Current status drugs. 1984;28:1-5.